Abstract 387P
Background
PD-1/PD-L1 inhibitor plus chemotherapy have shown tolerability and significant clinical benefits in pts with advanced TNBC. Antiangiogenic agent could remodel tumor blood vessels and increase the response to immune-checkpoint inhibitors (ICIs). AK105, an anti-PD-1 antibody, can effectively prevents PD-1 from binding to PD-L1 and PD-L2, and avoid immune evasion of tumor cells. Anlotinib is a novel antiangiogenic, multi-target tyrosine kinase inhibitor. This investigator initiated trial aims to investigate the efficacy and safety of AK105, anlotinib combined with nab-P as a first-line therapy in pts with advanced TNBC.
Methods
In this multicenter, prospective, single arm, phase 2 study, eligible pts were female aged 18-75 years, with ECOG PS 0-1, who had locally advanced or recurrent/metastatic triple-negative breast cancer. Eligible pts were treated with intravenous AK105 (200 mg on d1), oral anlotinib (12 mg once daily on d1-d14) and intravenous nab-P (125 mg/m2 on d1 and d8). The triplet combination regimen repeated every 21 days until disease progression, death or intolerable toxicity. The primary endpoint is ORR, and the secondary endpoints are DCR, PFS, OS and safety.
Results
From July 2022 to March 2024, 33 patients have been enrolled in this study. Median follow-up was 6.54 months (95% CI 2.68-11.43). Of all the patients whose efficacy could be evaluated (26/33), 1 (3.85%) patient achieved CR; 20 (76.92%), 4 (15.38%) and 1 (3.85%) patients got PR, SD and PD, respectively. ORR was 80.77 % (95% CI 60.65-93.45) and DCR was 96.15% (95% CI 80.36-99.90). The overall mPFS was 11.14 months (95% CI 8.34-18.04), the mOS have not reached. The most common AEs were grade 1 or 2. The grade 3 AEs (incidence ≥ 10%) included were neutropenia (33.33%), leukopenia (12.12%) and elevated AST (12.12%). There were two case of grade 4 neutropenia and one case of grade 4 hypertriglyceridemia. One death (from hepatitis) was considered by the investigators to be related to the trial regimen.
Conclusions
The combination of AK105, anlotinib and nab-P showed better treatment response and tolerable toxicity in the treatment of first-line patients with TNBC.
Clinical trial identification
NCT05244993.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chiatai Tianqing.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer
Presenter: Andreas Varkaris
Session: Poster session 15
385P - A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Presenter: David Page
Session: Poster session 15
388P - Anlotinib or bevacizumab combined with chemotherapy for the second-line HER-2 negative metastatic breast cancer: A retrospective cohort study
Presenter: jin xiang
Session: Poster session 15
390P - SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Presenter: Maria Cona
Session: Poster session 15
391P - Real-world activity of sacituzumab govitecan for metastatic breast cancer
Presenter: Stefania Morganti
Session: Poster session 15
392P - Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Adam Brufsky
Session: Poster session 15
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15